Verition Fund Management
ADMA icon

Verition Fund Management’s ADMA Biologics ADMA Stock Holding History

Verition Fund Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$901K – 2061
2026
Q1 		$901K Buy
+100,000
New +$1.58M 0.01% 1354
2025
Q4 		– Sell
-27,179
Closed -$398K – 3469
2025
Q3 		$398K Sell
27,179
-24,528
-47% -$420K ﹤0.01% 3148
2025
Q2 		$942K Buy
51,707
+2,349
+5% +$47.9K ﹤0.01% 2518
2025
Q1 		$979K Sell
49,358
-96,428
-66% -$1.67M ﹤0.01% 2141
2024
Q4 		$2.5M Sell
145,786
-199
-0.1% -$3.74K 0.01% 1408
2024
Q3 		$2.92M Buy
145,985
+134,739
+1,198% +$2.1M 0.01% 1185
2024
Q2 		$126K Buy
+11,246
New +$94.3K ﹤0.01% 2698
2023
Q3 		– Sell
-707,028
Closed -$2.61M – 2307
2023
Q2 		$2.61M Buy
707,028
+393,890
+126% +$1.46M 0.03% 562
2023
Q1 		$1.04M Sell
313,138
-261,920
-46% -$905K 0.01% 931
2022
Q4 		$2.23M Sell
575,058
-794,494
-58% -$2.45M 0.03% 581
2022
Q3 		$3.33M Buy
1,369,552
+1,344,560
+5,380% +$3.23M 0.04% 621
2022
Q2 		$49K Sell
24,992
-1,276,646
-98% -$2.51M ﹤0.01% 2149
2022
Q1 		$2.38M Buy
1,301,638
+797,749
+158% +$1.24M 0.03% 843
2021
Q4 		$710K Buy
+503,889
New +$662K 0.01% 1504

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Verition Fund Management's ADMA Position: Q2 2026 in Review

Verition Fund Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 100,000 shares — an estimated $901K sold.

Verition Fund Management first reported a position in ADMA in Q4 2021 and held it in 14 quarters. The position peaked at $3.33M in Q3 2022. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Verition Fund Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 100,000 ADMA Biologics shares in Q2 2026, an estimated $901K.
  • Verition Fund Management first reported a position in ADMA Biologics in Q4 2021 and held it in 14 quarters.
  • Verition Fund Management's ADMA Biologics position peaked at $3.33M in Q3 2022.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.